RxDoctor Payments DataLook up a doctor →

Mohammad Zaman, MD

Critical Care Medicine · Brooklyn, NYNPI 1477597367

Payments from drug & device makers

$13,009in general payments, 2019–2025

Across 547 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • AstraZeneca$1K
  • Insmed, Inc.$1K
  • Genentech USA, Inc.$497
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$12,21794%
  • Education$7926%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,009 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$138,925
Medicare patients
327
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter327$296,919
Breo ElliptaFluticasone/Vilanterol100$53,599
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$16,452
Albuterol Sulfate HfaAlbuterol Sulfate302$9,779
Arnuity ElliptaFluticasone Furoate20$4,376
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,404
Wixela InhubFluticasone Propion/Salmeterol21$2,013
Ventolin HfaAlbuterol Sulfate13$933
Azithromycin55$576
Montelukast Sodium35$511
Prednisone109$420
Fluticasone Propionate15$133
Pantoprazole Sodium13$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,794$354,894447 claims
AstraZenecaBreztri Aerosphere$1,187$16,45223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →